These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 28778025)

  • 1. Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Murakami K; Omoto Y; Iwase H
    Transl Oncol; 2017 Oct; 10(5):766-771. PubMed ID: 28778025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Sueta A; Tomiguchi M; Murakami K; Omoto Y; Iwase H
    BMC Cancer; 2017 Nov; 17(1):786. PubMed ID: 29166868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis.
    Urso L; Vernaci G; Carlet J; Lo Mele M; Fassan M; Zulato E; Faggioni G; Menichetti A; Di Liso E; Griguolo G; Falci C; Conte P; Indraccolo S; Guarneri V; Dieci MV
    Front Oncol; 2021; 11():625636. PubMed ID: 33777770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.
    Wang P; Bahreini A; Gyanchandani R; Lucas PC; Hartmaier RJ; Watters RJ; Jonnalagadda AR; Trejo Bittar HE; Berg A; Hamilton RL; Kurland BF; Weiss KR; Mathew A; Leone JP; Davidson NE; Nikiforova MN; Brufsky AM; Ambros TF; Stern AM; Puhalla SL; Lee AV; Oesterreich S
    Clin Cancer Res; 2016 Mar; 22(5):1130-7. PubMed ID: 26500237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole.
    Gyanchandani R; Kota KJ; Jonnalagadda AR; Minteer T; Knapick BA; Oesterreich S; Brufsky AM; Lee AV; Puhalla SL
    Oncotarget; 2017 Sep; 8(40):66901-66911. PubMed ID: 28978004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Implications of Monitoring ESR1 Mutations by Circulating Tumor DNA in Estrogen Receptor Positive Metastatic Breast Cancer: A Pilot Study.
    Li X; Lu J; Zhang L; Luo Y; Zhao Z; Li M
    Transl Oncol; 2020 Feb; 13(2):321-328. PubMed ID: 31877464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Inao T; Sueta A; Fujiwara S; Omoto Y; Iwase H
    Transl Res; 2015 Dec; 166(6):540-553.e2. PubMed ID: 26434753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.
    Chandarlapaty S; Chen D; He W; Sung P; Samoila A; You D; Bhatt T; Patel P; Voi M; Gnant M; Hortobagyi G; Baselga J; Moynahan ME
    JAMA Oncol; 2016 Oct; 2(10):1310-1315. PubMed ID: 27532364
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Stergiopoulou D; Markou A; Tzanikou E; Ladas I; Makrigiorgos GM; Georgoulias V; Lianidou E
    Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33535614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
    Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
    Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of sensitive and robust multiplex digital PCR assays for the detection of ESR1 mutations in the plasma of metastatic breast cancer patients.
    Corné J; Quillien V; Callens C; Portois P; Bidard FC; Jeannot E; Godey F; Le Du F; Robert L; Bourien H; Brunot A; Crouzet L; Perrin C; Lefeuvre-Plesse C; Diéras V; de la Motte Rouge T
    Clin Chim Acta; 2023 May; 545():117366. PubMed ID: 37105452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing.
    Yanagawa T; Kagara N; Miyake T; Tanei T; Naoi Y; Shimoda M; Shimazu K; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2017 Jun; 163(2):231-240. PubMed ID: 28283903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients.
    Beije N; Sieuwerts AM; Kraan J; Van NM; Onstenk W; Vitale SR; van der Vlugt-Daane M; Dirix LY; Brouwer A; Hamberg P; de Jongh FE; Jager A; Seynaeve CM; Jansen MPHM; Foekens JA; Martens JWM; Sleijfer S
    Mol Oncol; 2018 Jan; 12(1):48-57. PubMed ID: 29063679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical relevance of circulating ESR1 mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma.
    Drouyer A; Beaussire L; Jorda P; Leheurteur M; Guillemet C; Berghian A; Georgescu D; Di Fiore F; Perdrix A; Clatot F
    BMC Cancer; 2023 Nov; 23(1):1061. PubMed ID: 37924026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single droplet digital PCR for ESR1 activating mutations detection in plasma.
    Jeannot E; Darrigues L; Michel M; Stern MH; Pierga JY; Rampanou A; Melaabi S; Benoist C; Bièche I; Vincent-Salomon A; El Ayachy R; Noret A; Epaillard N; Cabel L; Bidard FC; Proudhon C
    Oncogene; 2020 Apr; 39(14):2987-2995. PubMed ID: 32042112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Inao T; Sueta A; Fujiwara S; Omoto Y; Iwase H
    Oncotarget; 2016 May; 7(22):32504-18. PubMed ID: 27102299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation analysis using cell-free DNA for endocrine therapy in patients with HR+ metastatic breast cancer.
    Sim SH; Yang HN; Jeon SY; Lee KS; Park IH
    Sci Rep; 2021 Mar; 11(1):5566. PubMed ID: 33692409
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Kumar M; Salem K; Michel C; Jeffery JJ; Yan Y; Fowler AM
    J Nucl Med; 2019 Sep; 60(9):1247-1252. PubMed ID: 30850489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multiplex allele-specific real-time PCR assay for screening of ESR1 mutations in metastatic breast cancer.
    Wang T; Liu JH; Zhang J; Wang L; Chen C; Dai PG
    Exp Mol Pathol; 2015 Apr; 98(2):152-7. PubMed ID: 25746663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.
    Guttery DS; Page K; Hills A; Woodley L; Marchese SD; Rghebi B; Hastings RK; Luo J; Pringle JH; Stebbing J; Coombes RC; Ali S; Shaw JA
    Clin Chem; 2015 Jul; 61(7):974-82. PubMed ID: 25979954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.